Subvenite (Lamotrigine) Patent Expiration, LOE Window & CMS Spending

Subvenite (Lamotrigine) by Owp: FDA Orange Book LOE 2040-05-29, 36 AB generics, $17K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorOwp
FDA Application & PathwayN218879 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2040-05-29
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors36
2024 CMS Total Public Spend$17K
2024 Medicare Part D Spend$12K
2024 Medicaid Spend$4K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel